Ptc Therapeutics (PTCT) Raw Materials (2019 - 2026)

Ptc Therapeutics' Raw Materials history runs 8 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 23.6% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 23.6% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 9.73% from the prior year.
• Raw Materials declined to $1.6 million in Q1 2026 per PTCT's latest filing, from $2.3 million in the prior quarter.
• Across five years, Raw Materials topped out at $2.7 million in Q3 2024 and bottomed at $907000.0 in Q3 2023.
• The 5-year median for Raw Materials is $1.4 million (2022), against an average of $1.6 million.
• Across the five-year window, Raw Materials dropped 26.92% in 2023 and surged 201.87% in 2024, its largest moves.
• Year by year, Raw Materials stood at $1.1 million in 2022, then decreased by 11.69% to $952000.0 in 2023, then soared by 166.6% to $2.5 million in 2024, then decreased by 9.73% to $2.3 million in 2025, then declined by 29.9% to $1.6 million in 2026.
• Per Business Quant, the three latest PTCT Raw Materials figures stand at $1.6 million (Q1 2026), $2.3 million (Q4 2025), and $2.2 million (Q3 2025).